The role of the PACAP signaling system in depression

Current Pharmaceutical Design

Volumn 17, Issue 10, 2011, Pages 990-1001

  Pinhasov, Albert ^a   Nesher, Elimelech ^a,c   Gross, Moshe ^a,c   Turgeman, Gadi ^a   Kreinin, Anatoly ^b   Yadid, Gal ^c  

^a ARIEL UNIVERSITY   (Israel)

^b Technion Medical School   (Israel)

^c BAR ILAN UNIVERSITY   (Israel)

Author keywords

Depression; Major Depressive Disorder; PAC1; PACAP; VIP; VPAC1; VPAC2

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; DESIPRAMINE; DESVENLAFAXINE; DOSULEPIN; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; IMIPRAMINE; ISOCARBOXAZID; LOFEPRAMINE; MAXADILAN; MILNACIPRAN; MOCLOBEMIDE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PIRLINDOLE; PROTRIPTYLINE; REBOXETINE; SELEGILINE; SERTRALINE; TRANYLCYPROMINE; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE; VILOXAZINE;

ALTERNATIVE RNA SPLICING; AMINO TERMINAL SEQUENCE; BRAIN DEVELOPMENT; DOPAMINERGIC SYSTEM; DRUG HALF LIFE; GENE MAPPING; GENETIC VARIABILITY; HUMAN; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; MONOAMINERGIC SYSTEM; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PLEIOTROPY; POSTTRAUMATIC STRESS DISORDER; PREVALENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN TARGETING; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC NERVE CELL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; SYNAPTIC TRANSMISSION;

EID: 79958117856     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211795589328     Document Type: Review

References (227)

1. Yaka R, He DY, Phamluong K, Ron D. Pituitary adenylate cyclaseactivating polypeptide (PACAP(1-38) enhances N-methyl-Daspartate receptor function and brain-derived neurotrophic factor expression via RACK1. J Biol Chem, 2003; 278: 9630-8.
2. Fahrenkrug J. VIP and PACAP. Results Probl Cell Differ, 2010; 50: 221-34.
3. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev, 2000; 52: 269-324.
4. Teuchner B, Dimmer A, Humpel C, et al. VIP, PACAP-38, BDNF and ADNP in NMDA-induced excitotoxicity in the rat retina. Acta Ophthalmol, 2010.
5. Yang K, Lei G, Jackson MF, Macdonald JF. The involvement of PACAP/VIP system in the synaptic transmission in the hippocampus. J Mol Neurosci, 2010; 42: 319-26.
6. Shintani N, Suetake S, Hashimoto H, et al. Neuroprotective action of endogenous PACAP in cultured rat cortical neurons. Regul Pept, 2005; 126: 123-8.
7. Reichenstein M, Rehavi M, Pinhasov A. Involvement of Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) and its Receptors in the Mechanism of Antidepressant Action. J Mol Neurosci, 2008; 36: 330-8.
8. Pellegri G, Magistretti PJ, Martin JL. VIP and PACAP potentiate the action of glutamate on BDNF expression in mouse cortical neurones. Eur J Neurosci, 1998; 10: 272-80.
9. Nussdorfer GG, Malendowicz LK. Role of VIP, PACAP, and related peptides in the regulation of the hypothalamo-pituitaryadrenal axis. Peptides, 1998; 19: 1443-67.
10. Nakamachi T, Nakamura K, Oshida K, et al. Pituitary adenylate cyclase-activating polypeptide (PACAP) stimulates proliferation of reactive astrocytes in vitro. J Mol Neurosci, 2011; 43: 16-21.
11. Kuri BA, Chan SA, Smith CB. PACAP regulates immediate catecholamine release from adrenal chromaffin cells in an activitydependent manner through a protein kinase C-dependent pathway. J Neurochem, 2009; 110: 1214-25.
12. Kosacka J, Schroder T, Bechmann I, et al. PACAP up-regulates the expression of apolipoprotein D in 3T3-L1 adipocytes. DRG/3T3-L1 co-cultures study. Neurosci Res, 2011; 69: 8-16.
13. Katayama T, Hattori T, Yamada K, Matsuzaki S, Tohyama M. Role of the PACAP-PAC1-DISC1 and PACAP-PAC1-stathmin1 systems in schizophrenia and bipolar disorder: novel treatment mechanisms? Pharmacogenomics, 2009; 10: 1967-78.
14. Horvath G, Brubel R, Kovacs K, et al. Effects of PACAP on oxidative stress-induced cell death in rat kidney and human hepatocyte cells. J Mol Neurosci, 2011; 43: 67-75.
15. Guillot TS, Richardson JR, Wang MZ, et al. PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity. Neuropeptides, 2008; 42: 423-34.
16. Grinevich V, Fournier A, Pelletier G. Effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on corticotropin-releasing hormone (CRH) gene expression in the rat hypothalamic paraventricular nucleus. Brain Res, 1997; 773: 190-6.
17. Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, Culler MD, Coy DH. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun, 1989; 164: 567-74.
18. Miyata A, Jiang L, Dahl RD, et al. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun, 1990; 170: 643-8.
19. Arimura A, Somogyvari-Vigh A, Miyata A, Mizuno K, Coy DH, Kitada C. Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes. Endocrinology, 1991; 129: 2787-9.
20. Ghatei MA, Takahashi K, Suzuki Y, Gardiner J, Jones PM, Bloom SR. Distribution, molecular characterization of pituitary adenylate cyclase-activating polypeptide and its precursor encoding messenger RNA in human and rat tissues. J Endocrinol, 1993; 136: 159-66.
21. Masuo Y, Suzuki N, Matsumoto H, et al. Regional distribution of pituitary adenylate cyclase activating polypeptide (PACAP) in the rat central nervous system as determined by sandwich-enzyme immunoassay. Brain Res, 1993; 602: 57-63.
22. Hannibal J, Mikkelsen JD, Clausen H, Holst JJ, Wulff BS, Fahrenkrug J. Gene expression of pituitary adenylate cyclase activating polypeptide (PACAP) in the rat hypothalamus. Regul Pept, 1995; 55: 133-48.
23. Piggins HD, Stamp JA, Burns J, Rusak B, Semba K. Distribution of pituitary adenylate cyclase activating polypeptide (PACAP) immunoreactivity in the hypothalamus and extended amygdala of the rat. J Comp Neurol, 1996; 376: 278-94.
24. Sherwood NM, Krueckl SL, McRory JE. The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev, 2000; 21: 619-70.
25. Laburthe M, Couvineau A, Gaudin P, Maoret JJ, Rouyer-Fessard C, Nicole P. Receptors for VIP, PACAP, secretin, GRF, glucagon, GLP-1, and other members of their new family of G protein-linked receptors: structure-function relationship with special reference to the human VIP-1 receptor. Ann N Y Acad Sci, 1996; 805: 94-109; discussion 110-01.
26. Vaudry D, Falluel-Morel A, Bourgault S, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev, 2009; 61: 283-357.
27. Reglodi D, Gyarmati J, Ertl T, et al. Alterations of pituitary adenylate cyclase-activating polypeptide-like immunoreactivity in the human plasma during pregnancy and after birth. J Endocrinol Invest, 2010; 33: 443-5.
28. Dow RC, Bennie J, Fink G. Pituitary adenylate cyclase-activating peptide-38 (PACAP)-38 is released into hypophysial portal blood in the normal male and female rat. J Endocrinol, 1994; 142: R1-4.
29. Tams JW, Johnsen AH, Fahrenkrug J. Identification of pituitary adenylate cyclase-activating polypeptide1-38-binding factor in human plasma, as ceruloplasmin. Biochem J, 1999; 341 (Pt 2): 271-6.
30. Watanabe J, Nakamachi T, Matsuno R, et al. Localization, characterization and function of pituitary adenylate cyclaseactivating polypeptide during brain development. Peptides, 2007; 28: 1713-9.
31. Tabarin A, Chen D, Hakanson R, Sundler F. Pituitary adenylate cyclase-activating peptide in the adrenal gland of mammals: distribution, characterization and responses to drugs. Neuroendocrinology, 1994; 59: 113-9.
32. Sundler F, Ekblad E, Absood A, Hakanson R, Koves K, Arimura A. Pituitary adenylate cyclase activating peptide: a novel vasoactive intestinal peptide-like neuropeptide in the gut. Neuroscience, 1992; 46: 439-54.
33. Koves K, Arimura A, Gorcs TG, Somogyvari-Vigh A. Comparative distribution of immunoreactive pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide in rat forebrain. Neuroendocrinology, 1991; 54: 159-69.
34. Fahrenkrug J, Hannibal J. Pituitary adenylate cyclase activating polypeptide innervation of the rat female reproductive tract and the associated paracervical ganglia: effect of capsaicin. Neuroscience, 1996; 73: 1049-60.
35. Pettersson LM, Heine T, Verge VM, Sundler F, Danielsen N. PACAP mRNA is expressed in rat spinal cord neurons. J Comp Neurol, 2004; 471: 85-96.
36. Hashimoto H. [Physiological significance of pituitary adenylate cyclase-activating polypeptide (PACAP) in the nervous system]. Yakugaku Zasshi, 2002; 122: 1109-21.
37. Mazzocchi G, Malendowicz LK, Neri G, et al. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland. Int J Mol Med, 2002; 9: 233-43.
38. Luts L, Sundler F. Peptide-containing nerve fibers in the parathyroid glands of different species. Regul Pept, 1994; 50: 147-58.
39. Miampamba M, Germano PM, Arli S, et al. Expression of pituitary adenylate cyclase-activating polypeptide and PACAP type 1 receptor in the rat gastric and colonic myenteric neurons. Regul Pept, 2002; 105: 145-54.
40. Hannibal J, Ekblad E, Mulder H, Sundler F, Fahrenkrug J. Pituitary adenylate cyclase activating polypeptide (PACAP) in the gastrointestinal tract of the rat: distribution and effects of capsaicin or denervation. Cell Tissue Res, 1998; 291: 65-79.
41. Botia B, Jolivel V, Burel D, et al. Neuroprotective Effects of PACAP Against Ethanol-Induced Toxicity in the Developing Rat Cerebellum. Neurotox Res, 2011; 19: 423-34.
42. Morio H, Tatsuno I, Hirai A, Tamura Y, Saito Y. Pituitary adenylate cyclase-activating polypeptide protects rat-cultured cortical neurons from glutamate-induced cytotoxicity. Brain Res, 1996; 741: 82-8.
43. Onoue S, Endo K, Ohshima K, Yajima T, Kashimoto K. The neuropeptide PACAP attenuates beta-amyloid (1-42)-induced toxicity in PC12 cells. Peptides, 2002; 23: 1471-8.
44. Takei N, Torres E, Yuhara A, et al. Pituitary adenylate cyclaseactivating polypeptide promotes the survival of basal forebrain cholinergic neurons in vitro and in vivo: comparison with effects of nerve growth factor. Eur J Neurosci, 2000; 12: 2273-80.
45. Lindholm D, Skoglosa Y, Takei N. Developmental regulation of pituitary adenylate cyclase activating polypeptide (PACAP) and its receptor 1 in rat brain: function of PACAP as a neurotrophic factor. Ann N Y Acad Sci, 1998; 865: 189-96.
46. Atlasz T, Szabadfi K, Kiss P, Tamas A, Toth G, Reglodi D, Gabriel R. Evaluation of the protective effects of PACAP with cell-specific markers in ischemia-induced retinal degeneration. Brain Res Bull, 2010; 81: 497-504.
47. Deguil J, Chavant F, Lafay-Chebassier C, Perault-Pochat MC, Fauconneau B, Pain S. Neuroprotective effect of PACAP on translational control alteration and cognitive decline in MPTP parkinsonian mice. Neurotox Res, 2010; 17: 142-55.
48. Brenneman DE, Hauser JM, Spong C, Phillips TM. Chemokine release is associated with the protective action of PACAP-38 against HIV envelope protein neurotoxicity. Neuropeptides, 2002; 36: 271-80.
49. Chen Y, Samal B, Hamelink CR, et al. Neuroprotection by endogenous and exogenous PACAP following stroke. Regul Pept, 2006; 137: 4-19.
50. Waschek JA. Multiple actions of pituitary adenylyl cyclase activating peptide in nervous system development and regeneration. Dev Neurosci, 2002; 24: 14-23.
51. Reglodi D, Somogyvari-Vigh A, Vigh S, Kozicz T, Arimura A. Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. Stroke, 2000; 31: 1411-7.
52. Shioda S, Ohtaki H, Nakamachi T, et al. Pleiotropic functions of PACAP in the CNS: neuroprotection and neurodevelopment. Ann N Y Acad Sci, 2006; 1070: 550-60.
53. Stumm R, Kolodziej A, Prinz V, Endres M, Wu DF, Hollt V. Pituitary adenylate cyclase-activating polypeptide is up-regulated in cortical pyramidal cells after focal ischemia and protects neurons from mild hypoxic/ischemic damage. J Neurochem, 2007; 103: 1666-81.
54. Ohtaki H, Nakamachi T, Dohi K, Shioda S. Role of PACAP in ischemic neural death. J Mol Neurosci, 2008; 36: 16-25.
55. Atlasz T, Szabadfi K, Kiss P, et al. PACAP-mediated neuroprotection of neurochemically identified cell types in MSGinduced retinal degeneration. J Mol Neurosci, 2008; 36: 97-104.
56. Brenneman DE. Neuroprotection: a comparative view of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Peptides, 2007; 28: 1720-6.
57. Harmar AJ, Arimura A, Gozes I, et al. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev, 1998; 50: 265-70.
58. Ohtaki T, Masuda Y, Ishibashi Y, Kitada C, Arimura A, Fujino M. Purification and characterization of the receptor for pituitary adenylate cyclase-activating polypeptide. J Biol Chem, 1993; 268: 26650-7.
59. Ohtaki T, Watanabe T, Ishibashi Y, et al. Molecular identification of receptor for pituitary adenylate cyclase activating polypeptide. Biochem Biophys Res Commun, 1990; 171: 838-44.
60. McCulloch DA, Lutz EM, Johnson MS, et al. ADP-ribosylation factor-dependent phospholipase D activation by VPAC receptors and a PAC(1) receptor splice variant. Mol Pharmacol, 2001; 59: 1523-32.
61. Dickson L, Finlayson K. VPAC and PAC receptors: From ligands to function. Pharmacol Ther, 2009; 121: 294-316.
62. Lam HC, Takahashi K, Ghatei MA, Kanse SM, Polak JM, Bloom SR. Binding sites of a novel neuropeptide pituitary-adenylatecyclase-activating polypeptide in the rat brain and lung. Eur J Biochem, 1990; 193: 725-9.
63. Gottschall PE, Tatsuno I, Miyata A, Arimura A. Characterization and distribution of binding sites for the hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide. Endocrinology, 1990; 127: 272-7.
64. Spengler D, Waeber C, Pantaloni C, et al. Differential signal transduction by five splice variants of the PACAP receptor. Nature, 1993; 365: 170-5.
65. Usdin TB, Bonner TI, Mezey E. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology, 1994; 135: 2662-80.
66. Girard BA, Lelievre V, Braas KM, et al. Noncompensation in peptide/receptor gene expression and distinct behavioral phenotypes in VIP-and PACAP-deficient mice. J Neurochem, 2006; 99: 499-513.
67. Laburthe M, Couvineau A, Tan V. Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides, 2007; 28: 1631-9.
68. Hashimoto H, Nogi H, Mori K, et al. Distribution of the mRNA for a pituitary adenylate cyclase-activating polypeptide receptor in the rat brain: an in situ hybridization study. J Comp Neurol, 1996; 371: 567-77.
69. Caberlotto L, Jimenez P, Overstreet DH, Hurd YL, Mathe AA, Fuxe K. Alterations in neuropeptide Y levels and Y1 binding sites in the Flinders Sensitive Line rats, a genetic animal model of depression. Neurosci Lett, 1999; 265: 191-4.
70. Charney DS, Deutch A. A functional neuroanatomy of anxiety and fear: implications for the pathophysiology and treatment of anxiety disorders. Crit Rev Neurobiol, 1996; 10: 419-46.
71. Otto C, Zuschratter W, Gass P, Schutz G. Presynaptic localization of the PACAP-typeI-receptor in hippocampal and cerebellar mossy fibres. Brain Res Mol Brain Res, 1999; 66: 163-74.
72. Shneider Y, Shtrauss Y, Yadid G, Pinhasov A. Differential expression of PACAP receptors in postnatal rat brain. Neuropeptides, 2010; 44: 509-14.
73. Journot L, Spengler D, Pantaloni C, Dumuis A, Sebben M, Bockaert J. The PACAP receptor: generation by alternative splicing of functional diversity among G protein-coupled receptors in nerve cells. Semin Cell Biol, 1994; 5: 263-72.
74. Pantaloni C, Brabet P, Bilanges B, et al. Alternative splicing in the N-terminal extracellular domain of the pituitary adenylate cyclaseactivating polypeptide (PACAP) receptor modulates receptor selectivity and relative potencies of PACAP-27 and PACAP-38 in phospholipase C activation. J Biol Chem, 1996; 271: 22146-51.
75. Dautzenberg FM, Mevenkamp G, Wille S, Hauger RL. N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants. J Neuroendocrinol, 1999; 11: 941-9.
76. Lutz EM, Ronaldson E, Shaw P, Johnson MS, Holland PJ, Mitchell R. Characterization of novel splice variants of the PAC1 receptor in human neuroblastoma cells: consequences for signaling by VIP and PACAP. Mol Cell Neurosci, 2006; 31: 193-209.
77. Chatterjee TK, Sharma RV, Fisher RA. Molecular cloning of a novel variant of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor that stimulates calcium influx by activation of L-type calcium channels. J Biol Chem, 1996; 271: 32226-32.
78. Sreedharan SP, Patel DR, Huang JX, Goetzl EJ. Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. Biochem Biophys Res Commun, 1993; 193: 546-53.
79. Ishihara T, Shigemoto R, Mori K, Takahashi K, Nagata S. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron, 1992; 8: 811-9.
80. Pisegna JR, Wank SA. Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor. Proc Natl Acad Sci U S A, 1993; 90: 6345-9.
81. Gourlet P, De Neef P, Cnudde J, Waelbroeck M, Robberecht P. In vitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptides, 1997; 18: 1555-60.
82. Nicole P, Lins L, Rouyer-Fessard C, et al. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide. J Biol Chem, 2000; 275: 24003-12.
83. Pisegna JR, Leyton J, Coelho T, et al. PACAP hybrid: a new PACAP receptor antagonist. Life Sci, 1997; 61: 631-9.
84. Xia M, Sreedharan SP, Bolin DR, Gaufo GO, Goetzl EJ. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. J Pharmacol Exp Ther, 1997; 281: 629-33.
85. Gozes I, Fridkinb M, Hill JM, Brenneman DE. Pharmaceutical VIP: prospects and problems. Curr Med Chem, 1999; 6: 1019-34.
86. Gozes I, Bachar M, Bardea A, Davidson A, Rubinraut S, Fridkin M, Giladi E. Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implications for early treatment of Alzheimer's disease. J Neurobiol, 1997; 33: 329-42.
87. Soleimani L, Lapidus KA, Iosifescu DV. Diagnosis and treatment of major depressive disorder. Neurol Clin, 2011; 29: 177-93, ix.
88. Amer. Psych. As. ed. Diagnostic and statistical manual of mental disorders fourth edition (text revision) DSM-IV-TR. American Psychiatric Publishing, Inc.: Washington, DC 2000.
89. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord, 2002; 68: 167-81.
90. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 2005; 62: 593-602.
91. Patten SB. Accumulation of major depressive episodes over time in a prospective study indicates that retrospectively assessed lifetime prevalence estimates are too low. BMC Psychiatry, 2009; 9: 19.
92. Kendler KS, Thornton LM, Gardner CO. Stressful life events and previous episodes in the etiology of major depression in women: an evaluation of the "kindling" hypothesis. Am J Psychiatry, 2000; 157: 1243-51.
93. Maletic V, Robinson M, Oakes T, Iyengar S, Ball SG, Russell J. Neurobiology of depression: an integrated view of key findings. Int J Clin Pract, 2007; 61: 2030-40.
94. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature, 2008; 455: 894-902.
95. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron, 2002; 34: 13-25.
96. Elhwuegi AS. Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry, 2004; 28: 435-51.
97. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med, 2001; 7: 541-7.
98. Lopez-Munoz F, Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des, 2009; 15: 1563-86.
99. Uppal A, Singh A, Gahtori P, Ghosh SK, Ahmad MZ. Antidepressants: Current Strategies and Future Opportunities. Curr Pharm Des, 2010.
100. Yadid G, Friedman A. Dynamics of the dopaminergic system as a key component to the understanding of depression. Prog Brain Res, 2008; 172: 265-86.
101. Papakostas GI, Petersen T, Denninger JW, et al. Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive disorder. Ann Clin Psychiatry, 2003; 15: 187-92.
102. Pacher P, Kohegyi E, Kecskemeti V, Furst S. Current trends in the development of new antidepressants. Curr Med Chem, 2001; 8: 89-100.
103. Pacher P, Kecskemeti V. Trends in the development of new antidepressants. Is there a light at the end of the tunnel? Curr Med Chem, 2004; 11: 925-43.
104. Berlim MT, Fleck MP, Turecki G. Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview. Ann Med, 2008; 40: 149-59.
105. Hokfelt T, Bartfai T, Bloom F. Neuropeptides: opportunities for drug discovery. Lancet Neurol, 2003; 2: 463-472.
106. Said SI. Influence of neuropeptides on airway smooth muscle. Am Rev Respir Dis, 1987; 136: S52-8.
107. Chaki S, Okubo T, Sekiguchi Y. Non-monoamine-based approach for the treatment of depression and anxiety disorders. Recent Pat CNS Drug Discov, 2006; 1: 1-27.
108. Holmes A, Heilig M, Rupniak NM, Steckler T, Griebel G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci, 2003; 24: 580-8.
109. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res, 1999; 33: 181-214.
110. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology, 2000; 23: 477-501.
111. Lundstrom L, Elmquist A, Bartfai T, Langel U. Galanin and its receptors in neurological disorders. Neuromolecular Med, 2005; 7: 157-80.
112. Griebel G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol Ther, 1999; 82: 1-61.
113. Hokfelt T, Broberger C, Xu ZQ, Sergeyev V, Ubink R, Diez M. Neuropeptides--an overview. Neuropharmacology, 2000; 39: 1337-56.
114. Rotzinger S, Lovejoy DA, Tan LA. Behavioral effects of neuropeptides in rodent models of depression and anxiety. Peptides, 2010; 31: 736-56.
115. Jimenez-Vasquez PA, Overstreet DH, Mathe AA. Neuropeptide Y in male and female brains of Flinders Sensitive Line, a rat model of depression. Effects of electroconvulsive stimuli. J Psychiatr Res, 2000; 34: 405-12.
116. Thorsell A, Slawecki CJ, El Khoury A, Mathe AA, Ehlers CL. The effects of social isolation on neuropeptide Y levels, exploratory and anxiety-related behaviors in rats. Pharmacol Biochem Behav, 2006; 83: 28-34.
117. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry, 2000; 157: 1552-62.
118. Charney DS, Manji HK. Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE, 2004; 2004: re5.
119. Duman RS, Malberg J, Nakagawa S, D'Sa C. Neuronal plasticity and survival in mood disorders. Biol Psychiatry, 2000; 48: 732-9.
120. Dencker SJ. The need for new and better antidepressants: reboxetine a new option. Acta Psychiatr Scand Suppl, 2000; 402: 6-11.
121. Fuller RW. Serotonin uptake inhibitors: uses in clinical therapy and in laboratory research. Prog Drug Res, 1995; 45: 167-204.
122. Kuhn R. The treatment of depressive states with G 22355 (imipramine hydrochloride). Am J Psychiatry, 1958; 115: 459-64.
123. Tamminga CA, Nemeroff CB, Blakely RD, et al. Murphy GM J, Paul SM, Rudorfer MV, Sausville E, Schatzberg AF, Scolnick EM, Suppes T. Developing novel treatments for mood disorders: accelerating discovery. Biol Psychiatry, 2002; 52: 589-609.
124. Delay J, Laine B, Buisson JF. [The action of isonicotinyl-hydrazide used in the treatment of depressive states]. Ann Med Psychol (Paris), 1952; 110: 689-92.
125. Zhang X, Gainetdinov RR, Beaulieu JM, et al. Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron, 2005; 45: 11-16.
126. Loosen PT, Marciniak R. Platelet MAO activity, TRH test, and dexamethasone suppression test in depressed patients. Pharmacopsychiatry, 1988; 21: 131-5.
127. Sherif F, Marcusson J, Oreland L. Brain gamma-aminobutyrate transaminase and monoamine oxidase activities in suicide victims. Eur Arch Psychiatry Clin Neurosci, 1991; 241: 139-44.
128. Schulze TG, Muller DJ, Krauss H, et al. Association between a functional polymorphism in the monoamine oxidase A gene promoter and major depressive disorder. Am J Med Genet, 2000; 96: 801-3.
129. Du L, Bakish D, Ravindran A, Hrdina PD. MAO-A gene polymorphisms are associated with major depression and sleep disturbance in males. Neuroreport, 2004; 15: 2097-101.
130. Ait-Ali D, Samal B, Mustafa T, Eiden LE. Neuropeptides, growth factors, and cytokines: a cohort of informational molecules whose expression is up-regulated by the stress-associated slow transmitter PACAP in chromaffin cells. Cell Mol Neurobiol, 2010; 30: 1441-9.
131. Marley PD, Cheung CY, Thomson KA, Murphy R. Activation of tyrosine hydroxylase by pituitary adenylate cyclase-activating polypeptide (PACAP-27) in bovine adrenal chromaffin cells. J Auton Nerv Syst, 1996; 60: 141-6.
132. Corbitt J, Vivekananda J, Wang SS, Strong R. Transcriptional and posttranscriptional control of tyrosine hydroxylase gene expression during persistent stimulation of pituitary adenylate cyclaseactivating polypeptide receptors on PC12 cells: regulation by protein kinase A-dependent and protein kinase A-independent pathways. J Neurochem, 1998; 71: 478-86.
133. Choi HJ, Park SY, Hwang O. Differential involvement of PKA and PKC in regulation of catecholamine enzyme genes by PACAP. Peptides, 1999; 20: 817-22.
134. Taupenot L, Mahata M, Mahata SK, O'Connor DT. Timedependent effects of the neuropeptide PACAP on catecholamine secretion: stimulation and desensitization. Hypertension, 1999; 34: 1152-62.
135. Tornoe K, Hannibal J, Jensen TB, et al. PACAP-(1-38) as neurotransmitter in the porcine adrenal glands. Am J Physiol Endocrinol Metab, 2000; 279: E1413-25.
136. Ravni A, Bourgault S, Lebon A, et al. The neurotrophic effects of PACAP in PC12 cells: control by multiple transduction pathways. J Neurochem, 2006; 98: 321-9.
137. Hashimoto H, Hashimoto R, Shintani N, et al. Depression-like behavior in the forced swimming test in PACAP-deficient mice: amelioration by the atypical antipsychotic risperidone. J Neurochem, 2009; 110: 595-602.
138. Reglodi D, Tamas A, Lengvari I, Toth G, Szalontay L, Lubics A. Comparative study of the effects of PACAP in young, aging, and castrated males in a rat model of Parkinson's disease. Ann N Y Acad Sci, 2006; 1070: 518-24.
139. Duman RS. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med, 2004; 5: 11-25.
140. Russo-Neustadt AA, Chen MJ. Brain-derived neurotrophic factor and antidepressant activity. Curr Pharm Des, 2005; 11: 1495-510.
141. Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci, 2007; 10: 1089-93.
142. Duman EN, Kesim M, Kadioglu M, Ulku C, Kalyoncu NI, Yaris E. Effect of gender on antinociceptive effect of paroxetine in hot plate test in mice. Prog Neuropsychopharmacol Biol Psychiatry, 2006; 30: 292-6.
143. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res, 2002; 109: 143-8.
144. Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, MacDonald E, Agerman K, Haapasalo A, Nawa H, Aloyz R, Ernfors P, Castren E. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci, 2003; 23: 349-57.
145. Yamada S, Yamamoto M, Ozawa H, Riederer P, Saito T. Reduced phosphorylation of cyclic AMP-responsive element binding protein in the postmortem orbitofrontal cortex of patients with major depressive disorder. J Neural Transm, 2003; 110: 671-80.
146. Yulug B, Ozan E, Kilic E. Brain-derived neurotrophic factor polymorphism as a genetic risk for depression? A short review of the literature. J Neuropsychiatry Clin Neurosci, 2010; 22: 123 E125-6.
147. Grunblatt E, Hupp E, Bambula M, et al. Association study of BDNF and CNTF polymorphism to depression in non-demented subjects of the "VITA" study. J Affect Disord, 2006; 96: 111-6.
148. Duman RS, Monteggia LM. A neurotrophic model for stressrelated mood disorders. Biol Psychiatry, 2006; 59: 1116-27.
149. Frechilla D, Garcia-Osta A, Palacios S, Cenarruzabeitia E, Del Rio J. BDNF mediates the neuroprotective effect of PACAP-38 on rat cortical neurons. Neuroreport, 2001; 12: 919-23.
150. Kozlovsky N, Matar MA, Kaplan Z, Kotler M, Zohar J, Cohen H. Long-term down-regulation of BDNF mRNA in rat hippocampal CA1 subregion correlates with PTSD-like behavioural stress response. Int J Neuropsychopharmacol, 2007; 10: 741-58.
151. Mitoma M, Yoshimura R, Sugita A, et al. Stress at work alters serum brain-derived neurotrophic factor (BDNF) levels and plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels in healthy volunteers: BDNF and MHPG as possible biological markers of mental stress? Prog Neuropsychopharmacol Biol Psychiatry, 2008; 32: 679-85.
152. Zink M, Otto C, Zorner B, et al. Reduced expression of brainderived neurotrophic factor in mice deficient for pituitary adenylate cyclase activating polypeptide type-I-receptor. Neurosci Lett, 2004; 360: 106-8.
153. Kidane AH, Roubos EW, Jenks BG. Pituitary adenylate cyclaseactivating polypeptide regulates brain-derived neurotrophic factor exon IV expression through the VPAC1 receptor in the amphibian melanotrope cell. Endocrinology, 2008; 149: 4177-82.
154. de Kloet ER, Joels M, Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev Neurosci, 2005; 6: 463-75.
155. de Kloet ER. About stress hormones and resilience to psychopathology. J Neuroendocrinol, 2008; 20: 885-92.
156. Malkesman O, Maayan R, Weizman A, Weller A. Aggressive behavior and HPA axis hormones after social isolation in adult rats of two different genetic animal models for depression. Behav Brain Res, 2006; 175: 408-14.
157. Pfennig A, Kunzel HE, Kern N, et al. Hypothalamus-pituitaryadrenal system regulation and suicidal behavior in depression. Biol Psychiatry, 2005; 57: 336-42.
158. Oitzl MS, Champagne DL, van der Veen R, de Kloet ER. Brain development under stress: hypotheses of glucocorticoid actions revisited. Neurosci Biobehav Rev, 2010; 34: 853-66.
159. Brown ES, Varghese FP, McEwen BS. Association of depression with medical illness: does cortisol play a role? Biol Psychiatry, 2004; 55: 1-9.
160. Weber B, Lewicka S, Deuschle M, Colla M, Vecsei P, Heuser I. Increased diurnal plasma concentrations of cortisone in depressed patients. J Clin Endocrinol Metab, 2000; 85: 1133-6.
161. Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry, 1988; 45: 577-9.
162. Raadsheer FC, van Heerikhuize JJ, Lucassen PJ, Hoogendijk WJ, Tilders FJ, Swaab DF. Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression. Am J Psychiatry, 1995; 152: 1372-6.
163. Weber CC, Eckert GP, Muller WE. Effects of antidepressants on the brain/plasma distribution of corticosterone. Neuropsychopharmacology, 2006; 31: 2443-8.
164. Stroth N, Eiden LE. Stress hormone synthesis in mouse hypothalamus and adrenal gland triggered by restraint is dependent on pituitary adenylate cyclase-activating polypeptide signaling. Neuroscience, 2010; 165: 1025-30.
165. Hannibal J. Pituitary adenylate cyclase-activating peptide in the rat central nervous system: an immunohistochemical and in situ hybridization study. J Comp Neurol, 2002; 453: 389-417.
166. Legradi G, Hannibal J, Lechan RM. Pituitary adenylate cyclaseactivating polypeptide-nerve terminals densely innervate corticotropin-releasing hormone-neurons in the hypothalamic paraventricular nucleus of the rat. Neurosci Lett, 1998; 246: 145-8.
167. Hannibal J, Jessop DS, Fahrenkrug J, Harbuz MS, Larsen PJ. PACAP gene expression in neurons of the rat hypothalamopituitary-adrenocortical axis is induced by endotoxin and interleukin-1beta. Neuroendocrinology, 1999; 70: 73-82.
168. Agarwal A, Halvorson LM, Legradi G. Pituitary adenylate cyclaseactivating polypeptide (PACAP) mimics neuroendocrine and behavioral manifestations of stress: Evidence for PKA-mediated expression of the corticotropin-releasing hormone (CRH) gene. Brain Res Mol Brain Res, 2005; 138: 45-57.
169. Norrholm SD, Das M, Legradi G. Behavioral effects of local microinfusion of pituitary adenylate cyclase activating polypeptide (PACAP) into the paraventricular nucleus of the hypothalamus (PVN). Regul Pept, 2005; 128: 33-41.
170. Dwivedi Y, Rizavi HS, Pandey GN. Antidepressants reverse corticosterone-mediated decrease in brain-derived neurotrophic factor expression: differential regulation of specific exons by antidepressants and corticosterone. Neuroscience, 2006; 139: 1017-29.
171. Schaaf MJ, de Jong J, de Kloet ER, Vreugdenhil E. Downregulation of BDNF mRNA and protein in the rat hippocampus by corticosterone. Brain Res, 1998; 813: 112-20.
172. Braas KM, Schutz KC, Bond JP, Vizzard MA, Girard BM, May V. Microarray analyses of pituitary adenylate cyclase activating polypeptide (PACAP)-regulated gene targets in sympathetic neurons. Peptides, 2007; 28: 1856-70.
173. Colwell CS, Michel S, Itri J, et al. Selective deficits in the circadian light response in mice lacking PACAP. Am J Physiol Regul Integr Comp Physiol, 2004; 287: R1194-201.
174. Hashimoto H, Shintani N, Tanaka K, et al. Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP). Proc Natl Acad Sci U S A, 2001; 98: 13355-60.
175. Hamelink C, Tjurmina O, Damadzic R, et al. Pituitary adenylate cyclase-activating polypeptide is a sympathoadrenal neurotransmitter involved in catecholamine regulation and glucohomeostasis. Proc Natl Acad Sci U S A, 2002; 99: 461-6.
176. Gray SL, Cummings KJ, Jirik FR, Sherwood NM. Targeted disruption of the pituitary adenylate cyclase-activating polypeptide gene results in early postnatal death associated with dysfunction of lipid and carbohydrate metabolism. Mol Endocrinol, 2001; 15: 1739-47.
177. Sandor K, Kormos V, Botz B, et al. Impaired nocifensive behaviours and mechanical hyperalgesia, but enhanced thermal allodynia in pituitary adenylate cyclase-activating polypeptide deficient mice. Neuropeptides, 2010; 44: 363-71.
178. Sandor K, Bolcskei K, McDougall JJ, et al. Divergent peripheral effects of pituitary adenylate cyclase-activating polypeptide-38 on nociception in rats and mice. Pain, 2009; 141: 143-50.
179. Shintani N, Hashimoto H, Tanaka K, et al. Serotonergic inhibition of intense jumping behavior in mice lacking PACAP (Adcyap1-/-). Ann N Y Acad Sci, 2006; 1070: 545-9.
180. Yamada K, Matsuzaki S, Hattori T, et al. Increased stathmin1 expression in the dentate gyrus of mice causes abnormal axonal arborizations. PLoS One, 2010; 5: e8596.
181. Shumyatsky GP, Malleret G, Shin RM, et al. stathmin, a gene enriched in the amygdala, controls both learned and innate fear. Cell, 2005; 123: 697-709.
182. Martel G, Nishi A, Shumyatsky GP. Stathmin reveals dissociable roles of the basolateral amygdala in parental and social behaviors. Proc Natl Acad Sci U S A, 2008; 105: 14620-25.
183. Otto C, Martin M, Wolfer DP, Lipp HP, Maldonado R, Schutz G. Altered emotional behavior in PACAP-type-I-receptor-deficient mice. Brain Res Mol Brain Res, 2001; 92: 78-84.
184. Nicot A, Otto T, Brabet P, Dicicco-Bloom EM. Altered social behavior in pituitary adenylate cyclase-activating polypeptide type I receptor-deficient mice. J Neurosci, 2004; 24: 8786-95.
185. Hosoya M, Kimura C, Ogi K, et al. Structure of the human pituitary adenylate cyclase activating polypeptide (PACAP) gene. Biochim Biophys Acta, 1992; 1129: 199-206.
186. Chang E, Welch S, Luna J, Giacalone J, Francke U. Generation of a human chromosome 18-specific YAC clone collection and mapping of 55 unique YACs by FISH and fingerprinting. Genomics, 1993; 17: 393-402.
187. Gozes I, Perl O, Zamostiano R, Rubinraut S, Fridkin M, Shochat L, Lewin LM. Multiple actions of a hybrid PACAP antagonist: neuronal cell killing and inhibition of sperm motility. Ann N Y Acad Sci, 1998; 865: 266-73.
188. Mukherjee O, Meera P, Ghosh S, et al. Evidence of linkage and association on 18p11.2 for psychosis. Am J Med Genet B Neuropsychiatr Genet, 2006; 141B: 868-73.
189. Hashimoto R, Hashimoto H, Shintani N, et al. Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia. Mol Psychiatry, 2007; 12: 1026-32.
190. Hashimoto R, Hashimoto H, Shintani N, et al. Possible association between the pituitary adenylate cyclase-activating polypeptide (PACAP) gene and major depressive disorder. Neurosci Lett, 2010; 468: 300-2.
191. Hattori T, Baba K, Matsuzaki S, et al. A novel DISC1-interacting partner DISC1-Binding Zinc-finger protein: implication in the modulation of DISC1-dependent neurite outgrowth. Mol Psychiatry, 2007; 12: 398-407.
192. Millar JK, Wilson-Annan JC, Anderson S, et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet, 2000; 9: 1415-23.
193. Hashimoto R, Numakawa T, Ohnishi T, et al. Impact of the DISC1 Ser704Cys polymorphism on risk for major depression, brain morphology and ERK signaling. Hum Mol Genet, 2006; 15: 3024-33.
194. Ressler KJ, Mercer KB, Bradley B, et al. Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature, 2011; 470: 492-7.
195. Dranovsky A, Hen R. Hippocampal Neurogenesis: Regulation by Stress and Antidepressants. Biological Psychiatry, 2006; 59: 1136-43.
196. Thomas RM, Hotsenpiller G, Peterson DA. Acute Psychosocial Stress Reduces Cell Survival in Adult Hippocampal Neurogenesis without Altering Proliferation. Journal of Neuroscience, 2007; 27: 2734-43.
197. Balu DT, Lucki I. Adult hippocampal neurogenesis: Regulation, functional implications, and contribution to disease pathology. Neuroscience & Biobehavioral Reviews, 2009; 33: 232-252.
198. Kaneko N, Sawamoto K. Adult neurogenesis and its alteration under pathological conditions. Neuroscience Research, 2009; 63: 155-64.
199. Vollmayr B, Mahlstedt M, Henn F. Neurogenesis and depression: what animal models tell us about the link. European Archives of Psychiatry and Clinical Neuroscience, 2007; 257: 300-303.
200. McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev, 2007; 87: 873-904.
201. Parker KJ, Schatzberg AF, Lyons DM. Neuroendocrine aspects of hypercortisolism in major depression. Horm Behav, 2003; 43: 60-6.
202. Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry, 2003; 160: 1554-65.
203. Kempermann G, Krebs J, Fabel K. The contribution of failing adult hippocampal neurogenesis to psychiatric disorders. Current Opinion in Psychiatry, 2008; 21: 290-5.
204. DeCarolis NA, Eisch AJ. Hippocampal neurogenesis as a target for the treatment of mental illness: A_critical evaluation. Neuropharmacology, 2010; 58: 884-93.
205. Scaccianoce S, Del Bianco P, Paolone G, et al. Social isolation selectively reduces hippocampal brain-derived neurotrophic factor without altering plasma corticosterone. Behav Brain Res, 2006; 168: 323-5.
206. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci, 2006; 9: 519-25.
207. Tfilin M, Sudai E, Merenlender A, Gispan I, Yadid G, Turgeman G. Mesenchymal stem cells increase hippocampal neurogenesis and counteract depressive-like behavior. Mol Psychiatry, 2010; 15: 1164-75.
208. Hu Z, Lelievre V, Rodriguez WI, et al. Embryonic expression of pituitary adenylyl cyclase-activating polypeptide and its selective type I receptor gene in the frog Xenopus laevis neural tube. The Journal of Comparative Neurology, 2001; 441: 266-75.
209. Waschek JA, Casillas RA, Nguyen TB, DiCicco-Bloom EM, Carpenter EM, Rodriguez WI. Neural tube expression of pituitary adenylate cyclase-activating peptide (PACAP) and receptor: Potential role in patterning and neurogenesis. Proceedings of the National Academy of Sciences of the United States of America, 1998; 95: 9602-7.
210. Allais Al, Burel D, Isaac ER, et al. Altered cerebellar development in mice lacking pituitary adenylate cyclase-activating polypeptide. European Journal of Neuroscience, 2007; 25: 2604-18.
211. Jaworski DM, Proctor MD. Developmental regulation of pituitary adenylate cyclase-activating polypeptide and PAC1 receptor mRNA expression in the rat central nervous system. Developmental Brain Research, 2000; 120: 27-39.
212. Basille M, Vaudry D, Coulouarn Y, et al. Comparative distribution of pituitary adenylate cyclase-activating polypeptide (PACAP) binding sites and PACAP receptor mRNAs in the rat brain during development. The Journal of Comparative Neurology, 2000; 425: 495-509.
213. Nicot A, DiCicco-Bloom E. Regulation of neuroblast mitosis is determined by PACAP receptor isoform expression. Proceedings of the National Academy of Sciences of the United States of America, 2001; 98: 4758-63.
214. Nishimoto M, Furuta A, Aoki S, Kudo Y, Miyakawa H, Wada K. PACAP/PAC1 autocrine system promotes proliferation and astrogenesis in neural progenitor cells. Glia, 2007; 55: 317-27.
215. Ohta S, Gregg C, Weiss S. Pituitary adenylate cyclase-activating polypeptide regulates forebrain neural stem cells and neurogenesis in vitro and in vivo. Journal of Neuroscience Research, 2006; 84: 1177-86.
216. McIlvain HB, Baudy A, Sullivan K, et al. Pituitary adenylate cyclase-activating peptide (PACAP) induces differentiation in the neuronal F11 cell line through a PKA-dependent pathway. Brain Research, 2006; 1077: 16-23.
217. Mercer A, Ronnholm H, Holmberg J, et al. PACAP promotes neural stem cell proliferation in adult mouse brain. Journal of Neuroscience Research, 2004; 76: 205-15.
218. Scharf E, May V, Braas K, Shutz K, Mao-Draayer Y. Pituitary Adenylate Cyclase-activating Polypeptide (PACAP) and Vasoactive Intestinal Peptide (VIP) Regulate Murine Neural Progenitor Cell Survival, Proliferation, and Differentiation. Journal of Molecular Neuroscience, 2008; 36: 79-88.
219. Watanabe J, Ohba M, Ohno F, et al. Pituitary adenylate cyclaseactivating polypeptide-induced differentiation of embryonic neural stem cells into astrocytes is mediated via the __ isoform of protein kinase C. Journal of Neuroscience Research, 2006; 84: 1645-55.
220. Hirose MEGU, Hashimoto HITO, Iga JUNK, Shintani NORI, Nakanishi MEGU, Arakawa NAOH, Shimada TAKE, Baba AKEM. Inhibition of Self-Renewal and Induction of Neural Differentiation by PACAP in Neural Progenitor Cells. Annals of the New York Academy of Sciences, 2006; 1070: 342-7.
221. Ohno F, Watanabe J, Sekihara H, et al. Pituitary adenylate cyclaseactivating polypeptide promotes differentiation of mouse neural stem cells into astrocytes. Regulatory Peptides, 2005; 126: 115-22.
222. Chafai MAGD, Louiset ESTE, Basille MAGA, et al. PACAP and VIP Promote Initiation of Electrophysiological Activity in Differentiating Embryonic Stem Cells. Annals of the New York Academy of Sciences, 2006; 1070: 185-9.
223. Cazillis Ml, Gonzalez BJ, Billardon C, et al. VIP and PACAP induce selective neuronal differentiation of mouse embryonic stem cells. European Journal of Neuroscience, 2004; 19: 798-808.
224. Tzeng SF, Huang HY. Downregulation of inducible nitric oxide synthetase by neurotrophin-3 in microglia. J Cell Biochem, 2003; 90: 227-33.
225. Ago Y, Yoneyama M, Ishihama T, et al. Role of endogenous pituitary adenylate cyclase-activating polypeptide in adult hippocampal neurogenesis. Neuroscience, 2011; 172: 554-61.
226. Overstreet DH, Friedman E, Mathe AA, Yadid G. The Flinders Sensitive Line rat: a selectively bred putative animal model of depression. Neurosci Biobehav Rev, 2005; 29: 739-59.
227. Feder Y, Nesher E, Ogran A, et al. Selective breeding for dominant and submissive behavior in Sabra mice. J Affect Disord, 2010; 126: 214-22.